Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Hisamitsu Pharmaceutical Co stock price, quote, forecast and news

4530.T
JP3784600003
864341

Price

4,096.00
Today +/-
+0
Today %
+0 %
P

Hisamitsu Pharmaceutical Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Hisamitsu Pharmaceutical Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Hisamitsu Pharmaceutical Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Hisamitsu Pharmaceutical Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Hisamitsu Pharmaceutical Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Hisamitsu Pharmaceutical Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Hisamitsu Pharmaceutical Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Hisamitsu Pharmaceutical Co’s growth potential.

Hisamitsu Pharmaceutical Co Revenue, EBIT and net profit per share

DateHisamitsu Pharmaceutical Co RevenueHisamitsu Pharmaceutical Co EBITHisamitsu Pharmaceutical Co Net Income
2027e167.66 B undefined0 undefined20.65 B undefined
2026e159.58 B undefined0 undefined16.54 B undefined
2025e154.53 B undefined0 undefined15.94 B undefined
2024141.71 B undefined13.17 B undefined13.97 B undefined
2023128.33 B undefined11.6 B undefined11.74 B undefined
2022120.19 B undefined9.34 B undefined9.66 B undefined
2021114.51 B undefined10.67 B undefined9.25 B undefined
2020140.99 B undefined22.73 B undefined18.69 B undefined
2019143.41 B undefined22.28 B undefined19.2 B undefined
2018148.47 B undefined26.94 B undefined19.12 B undefined
2017145.93 B undefined26.31 B undefined20.4 B undefined
2016161.85 B undefined27.73 B undefined17.78 B undefined
2015156.74 B undefined16.43 B undefined18.78 B undefined
2014150.64 B undefined19.12 B undefined21.36 B undefined
2013142.77 B undefined25.33 B undefined18.81 B undefined
2012137.79 B undefined25.94 B undefined18.44 B undefined
2011137.18 B undefined28.2 B undefined20.96 B undefined
2010129.83 B undefined28.59 B undefined18.42 B undefined
2009124.66 B undefined32.53 B undefined19.12 B undefined
2008119.06 B undefined29.1 B undefined18.66 B undefined
2007109.79 B undefined26.16 B undefined15.85 B undefined
2006102.67 B undefined22.8 B undefined14.39 B undefined
200583.55 B undefined21.52 B undefined12.81 B undefined

Hisamitsu Pharmaceutical Co Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)EBIT (B)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (M)DOCUMENTS
19941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025e2026e2027e
35.6736.236.5840.4746.8649.1154.6365.2469.547074.5983.55102.67109.79119.06124.66129.83137.18137.79142.77150.64156.74161.85145.93148.47143.41140.99114.51120.19128.33141.71154.53159.58167.66
-1.481.0610.6215.794.8111.2219.436.590.666.5512.0122.896.948.444.704.155.660.443.615.514.053.26-9.841.74-3.41-1.68-18.784.966.7710.429.053.275.06
60.9661.0661.8163.5167.0667.6269.4969.2470.2269.7568.8870.4170.9370.0369.6868.0067.1465.2366.0563.8263.1863.5963.9763.5762.4961.8462.1360.4158.3056.6555.73---
21.7522.1122.6125.731.4333.2137.9645.1748.8348.8351.3858.8272.8376.8982.9684.7787.1889.4991.0191.1195.1699.68103.5392.7792.7888.6887.669.1770.0772.778.97000
4.484.764.656.788.338.7511.1913.9916.0717.0618.0121.5222.826.1629.132.5328.5928.225.9425.3319.1216.4327.7326.3126.9422.2822.7310.679.3411.613.17000
12.5713.1412.7016.7517.7717.8220.4821.4523.1124.3724.1525.7622.2023.8224.4426.1022.0220.5518.8217.7412.6910.4817.1318.0318.1515.5316.129.327.779.049.29---
1.531.551.681.832.413.874.486.798.619.410.7812.8114.3915.8518.6619.1218.4220.9618.4418.8121.3618.7817.7820.419.1219.218.699.259.6611.7413.9715.9416.5420.65
-0.988.419.1931.8060.5315.6551.5926.809.1814.7418.8412.3010.1317.772.45-3.6513.75-12.012.0113.55-12.05-5.3214.68-6.260.44-2.66-50.524.4121.5818.9714.123.7624.85
----------------------------------
----------------------------------
94949494949596939493919190898989878986868685.6785.1984.5883.7383.5582.2581.7981.2779.4177000
----------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Hisamitsu Pharmaceutical Co Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Hisamitsu Pharmaceutical Co is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Hisamitsu Pharmaceutical Co provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Hisamitsu Pharmaceutical Co's financial health and stability.

Assets

Hisamitsu Pharmaceutical Co's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Hisamitsu Pharmaceutical Co must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Hisamitsu Pharmaceutical Co after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Hisamitsu Pharmaceutical Co's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)DEPRECIATION (B)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (B)NON-CASH ITEM (B)PAID INTEREST (M)PAID TAXES (B)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (B)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (B)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
11.9815.6616.5917.8721.924.5125.9230.2132.2131.8536.132.3831.9933.7329.4227.9229.9827.6925.6726.1612.212.9616.11
2.852.613.133.543.315.185.225.526.887.627.156.97.597.496.678.557.376.015.744.254.084.324.95
00000000000000000000000
-3.18-6.51-6.31-14.52-4.9-7.22-20.28-10.61-18.96-18.71-2.64-7.96-1.953.36-7.2-3.35-15.4-2.44-12.62-1.32-9.244.74-4.53
0.631.321.330.99-0.180.451.370.62.25-0.27-4.28-5.76-5.15-8.73-6.6-2.19-2.05-0.81-3.02-1.69-1.75-2.81-3.8
1737918428344134211910812592383534333932191992015
5.16.393.299.647.139.0811.569.1812.7516.8311.818.489.8413.3513.878.5511.236.949.342.947.320.515.33
12.2813.0814.747.8820.1322.9112.2325.7222.3820.4936.3425.5632.4835.8523.2330.9219.9130.4515.7727.395.2919.212.73
-3,783-5,008-7,309-3,297-2,297-4,977-5,641-9,562-5,986-7,050-6,164-15,779-5,635-4,208-4,871-5,149-3,199-3,340-3,663-3,726-3,388-4,193-7,908
-5.13-6.59-9.2-2.26-4.76-18.61-11.81-11.91-15.93-32.55-8.25-15.48-7.95-5.84-8.95-3.911.07-1.38-39.3-17.237.82-13.06-23.87
-1.35-1.58-1.891.04-2.46-13.63-6.17-2.35-9.94-25.5-2.090.3-2.31-1.64-4.071.244.271.96-35.64-13.511.2-8.87-15.96
00000000000000000000000
-0.02-3.23-0.580.610.127.12-4.85-2.650.0916.7-9.5-3.46-3.01-0.18-0.12-0.08-0.19-0.17-0.17-0.22-0.17-0.12-0.07
-880-1,636-3,213-1,763-75-5,764-9-8-66-5,948-3-3,3170-3-1-4,178-11,152-2-6,176-4,520-2-8,043-7,694
-1.51-5.53-4.54-2.4-1.27-0.3-9.58-7.48-5.474.9-15.66-13.01-9.29-6.48-7.04-11.62-18.4-7.15-13.35-11.73-7.19-15.19-14.69
-124094-137-35-27-35-34-57-82-179-205-274-295-276-290-113-125-118-153-210-190-203
-481-665-847-1,104-1,270-1,633-4,689-4,790-5,433-5,773-5,980-6,031-6,000-5,998-6,642-7,067-6,944-6,855-6,882-6,836-6,806-6,839-6,719
5.691.040.753.1114.064.15-9.116.20.65-7.1311.42-3.4316.6426.9210.8315.331.6720.96-37.79-1.794.36-5.11-20.82
8,4978,0707,4304,57917,83217,9286,58916,15716,39413,44430,1769,77926,84931,63718,36125,77216,71127,11312,10823,6681,90015,0064,820
00000000000000000000000

Hisamitsu Pharmaceutical Co stock margins

The Hisamitsu Pharmaceutical Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Hisamitsu Pharmaceutical Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Hisamitsu Pharmaceutical Co.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Hisamitsu Pharmaceutical Co's sales revenue. A higher gross margin percentage indicates that the Hisamitsu Pharmaceutical Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Hisamitsu Pharmaceutical Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Hisamitsu Pharmaceutical Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Hisamitsu Pharmaceutical Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Hisamitsu Pharmaceutical Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Hisamitsu Pharmaceutical Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Hisamitsu Pharmaceutical Co Margin History

Hisamitsu Pharmaceutical Co Gross marginHisamitsu Pharmaceutical Co Profit marginHisamitsu Pharmaceutical Co EBIT marginHisamitsu Pharmaceutical Co Profit margin
2027e55.73 %0 %12.32 %
2026e55.73 %0 %10.37 %
2025e55.73 %0 %10.32 %
202455.73 %9.29 %9.86 %
202356.65 %9.04 %9.15 %
202258.3 %7.77 %8.04 %
202160.41 %9.32 %8.08 %
202062.13 %16.12 %13.26 %
201961.84 %15.53 %13.39 %
201862.49 %18.15 %12.88 %
201763.57 %18.03 %13.98 %
201663.97 %17.13 %10.99 %
201563.59 %10.48 %11.98 %
201463.18 %12.69 %14.18 %
201363.82 %17.74 %13.17 %
201266.05 %18.82 %13.38 %
201165.23 %20.55 %15.28 %
201067.14 %22.02 %14.19 %
200968 %26.1 %15.34 %
200869.68 %24.44 %15.68 %
200770.03 %23.82 %14.43 %
200670.93 %22.2 %14.02 %
200570.41 %25.76 %15.34 %

Hisamitsu Pharmaceutical Co Stock Sales Revenue, EBIT, Earnings per Share

The Hisamitsu Pharmaceutical Co earnings per share therefore indicates how much revenue Hisamitsu Pharmaceutical Co has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Hisamitsu Pharmaceutical Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Hisamitsu Pharmaceutical Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Hisamitsu Pharmaceutical Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Hisamitsu Pharmaceutical Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Hisamitsu Pharmaceutical Co Revenue, EBIT and net profit per share

DateHisamitsu Pharmaceutical Co Sales per ShareHisamitsu Pharmaceutical Co EBIT per shareHisamitsu Pharmaceutical Co Earnings per Share
2027e2,285.97 undefined0 undefined281.59 undefined
2026e2,175.8 undefined0 undefined225.53 undefined
2025e2,106.95 undefined0 undefined217.35 undefined
20241,840.27 undefined170.99 undefined181.41 undefined
20231,616.12 undefined146.07 undefined147.87 undefined
20221,478.93 undefined114.89 undefined118.84 undefined
20211,400.12 undefined130.47 undefined113.1 undefined
20201,714.29 undefined276.33 undefined227.3 undefined
20191,716.45 undefined266.65 undefined229.85 undefined
20181,773.17 undefined321.75 undefined228.34 undefined
20171,725.37 undefined311.03 undefined241.14 undefined
20161,899.94 undefined325.52 undefined208.76 undefined
20151,829.68 undefined191.75 undefined219.27 undefined
20141,751.57 undefined222.36 undefined248.34 undefined
20131,660.14 undefined294.49 undefined218.71 undefined
20121,602.26 undefined301.62 undefined214.41 undefined
20111,541.39 undefined316.8 undefined235.46 undefined
20101,492.34 undefined328.57 undefined211.76 undefined
20091,400.62 undefined365.53 undefined214.83 undefined
20081,337.76 undefined326.92 undefined209.7 undefined
20071,233.61 undefined293.9 undefined178.06 undefined
20061,140.72 undefined253.28 undefined159.88 undefined
2005918.08 undefined236.48 undefined140.8 undefined

Hisamitsu Pharmaceutical Co business model

Hisamitsu Pharmaceutical Co Inc is a Japanese company that was founded in 1847. The company is known for its patches and other medical products, making it one of the largest pharmaceutical manufacturers in Japan. The company specializes in the development and production of pharmaceuticals, medical devices, and health and beauty products. They have four main business areas: pharmaceutical products, health products, medical devices, and cosmetics. In addition to their popular Salonpas patches, they also offer a range of other medications, health products, medical devices, and cosmetics. Hisamitsu is committed to improving health and well-being through innovation and collaboration with research institutions and universities. Hisamitsu Pharmaceutical Co is one of the most popular companies on Eulerpool.com.

Hisamitsu Pharmaceutical Co SWOT Analysis

Strengths

Hisamitsu Pharmaceutical Co Inc possesses several strengths that contribute to its success:

  • Strong product portfolio, including well-known brands and a diverse range of healthcare products
  • Research and development capabilities, allowing the company to innovate and develop new drugs and treatments
  • Established market presence in multiple geographic regions, providing a global reach
  • Robust distribution network, ensuring widespread availability of products
  • Strong financial position, allowing for investment in growth opportunities and acquisitions

Weaknesses

Despite its strengths, Hisamitsu Pharmaceutical Co Inc faces a few weaknesses that need to be addressed:

  • Dependence on a limited number of key products, making the company vulnerable to market fluctuations
  • Relatively small market share compared to some competitors, limiting its bargaining power with suppliers and retailers
  • Challenges in maintaining brand loyalty due to intense competition in the pharmaceutical industry
  • Potential regulatory hurdles and compliance issues that could impact the company's operations

Opportunities

Hisamitsu Pharmaceutical Co Inc can leverage the following opportunities to drive growth and expand its market presence:

  • Increasing demand for healthcare products and treatments, driven by aging populations and rising health consciousness
  • Expansion into emerging markets with high growth potential, such as Asia-Pacific and Latin America
  • Collaboration and partnerships with other pharmaceutical companies or research institutions to accelerate product development
  • Growing trend towards personalized medicine, allowing for customization of treatments based on individual needs

Threats

Hisamitsu Pharmaceutical Co Inc should be mindful of the following threats that could impact its business:

  • Intense competition from both established pharmaceutical companies and generic drug manufacturers
  • Stringent regulations and compliance requirements in the pharmaceutical industry, increasing operational costs
  • Potential disruptions in the global supply chain, impacting the availability of raw materials and finished products
  • Increased scrutiny on drug pricing and healthcare affordability, potentially affecting profit margins

Hisamitsu Pharmaceutical Co historical P/E ratio, EBIT, and P/S ratio.

Hisamitsu Pharmaceutical Co shares outstanding

The number of shares was Hisamitsu Pharmaceutical Co in 2023 — This indicates how many shares 79.406 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Hisamitsu Pharmaceutical Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Hisamitsu Pharmaceutical Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Hisamitsu Pharmaceutical Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Hisamitsu Pharmaceutical Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Hisamitsu Pharmaceutical Co Stock splits

In Hisamitsu Pharmaceutical Co's history, there have been no stock splits.

Hisamitsu Pharmaceutical Co dividend history and estimates

In 2023, Hisamitsu Pharmaceutical Co paid a dividend amounting to 42.75 JPY. Dividend means that Hisamitsu Pharmaceutical Co distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Hisamitsu Pharmaceutical Co provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Hisamitsu Pharmaceutical Co’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Hisamitsu Pharmaceutical Co's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Hisamitsu Pharmaceutical Co Dividend History

DateHisamitsu Pharmaceutical Co Dividend
2027e45.36 undefined
2026e45.36 undefined
2025e45.42 undefined
202444.5 undefined
202342.75 undefined
202242.25 undefined
202183.75 undefined
202083.25 undefined
201982.75 undefined
201882.25 undefined
201782 undefined
201641.5 undefined
201582.5 undefined
201442.5 undefined
201370 undefined
201270 undefined
201170 undefined
201069 undefined
200965.5 undefined
200861.5 undefined
200729 undefined
200653 undefined
200516 undefined

Hisamitsu Pharmaceutical Co dividend payout ratio

In 2023, Hisamitsu Pharmaceutical Co had a payout ratio of 48.74%. The payout ratio indicates the percentage of the company's profits that Hisamitsu Pharmaceutical Co distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Hisamitsu Pharmaceutical Co represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Hisamitsu Pharmaceutical Co could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Hisamitsu Pharmaceutical Co's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Hisamitsu Pharmaceutical Co Payout Ratio History

DateHisamitsu Pharmaceutical Co Payout ratio
2027e49.18 %
2026e49.07 %
2025e45.69 %
202452.78 %
202348.74 %
202235.55 %
202174.05 %
202036.63 %
201936 %
201836.02 %
201734 %
201619.88 %
201537.63 %
201417.11 %
201332.01 %
201232.65 %
201129.73 %
201032.59 %
200930.49 %
200829.33 %
200716.29 %
200633.15 %
200511.36 %
Unfortunately, there are currently no price targets and forecasts available for Hisamitsu Pharmaceutical Co.

Hisamitsu Pharmaceutical Co latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/202453.73 63.89  (18.9 %)2025 Q1
6/30/202319.59 52.08  (165.8 %)2024 Q1
6/30/202121.01 28.91  (37.61 %)2022 Q1
6/30/202031.21 1.39  (-95.55 %)2021 Q1
6/30/201857.97 41.27  (-28.81 %)2019 Q1
6/30/201661.71 53.5  (-13.31 %)2017 Q1
6/30/201554.24 41.27  (-23.91 %)2016 Q1
1

Eulerpool ESG Scorecard© for the Hisamitsu Pharmaceutical Co stock

Eulerpool World ESG Rating (EESG©)

56/ 100

🌱 Environment

66

👫 Social

65

🏛️ Governance

37

Environment

Scope 1 - Direct Emissions
6,923
Scope 2 - Indirect emissions from purchased energy
15,862
Scope 3 - Indirect emissions within the value chain
26,252
Total CO₂ emissions
22,785
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
✅

Social

Percentage of female employees29.49
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement✅
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Hisamitsu Pharmaceutical Co list of shareholders

%
Name
Stocks
Change
Date
6.75 % MUFG Bank, Ltd.4,952,1844,952,1841/22/2024
5.75 % INVESCO Asset Management (Japan) Ltd.4,215,2002,839,6008/15/2023
5.65 % Nomura Trust & Banking (Trust)4,143,000-84,0008/31/2023
5.33 % Nippon Life Insurance Company3,910,00008/31/2023
4.60 % The Bank of Fukuoka, Ltd.3,371,00008/31/2023
3.54 % Hisamitsu Pharmaceutical Co., Inc. Customers2,593,00069,0008/31/2023
3.21 % The Bank of Saga, Ltd.2,356,00008/31/2023
3.05 % Mitsubishi UFJ Trust and Banking Corporation2,233,7302,233,7301/22/2024
2.81 % SMBC Trust Bank (Trust)2,064,00008/31/2023
2.52 % The Vanguard Group, Inc.1,847,009-45,5003/31/2024
1
2
3
4
5
...
10

Hisamitsu Pharmaceutical Co Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Alfresa Holdings Stock
Alfresa Holdings
SupplierCustomer0,530,620,61-0,470,060,62
Medipal Holdings Stock
Medipal Holdings
SupplierCustomer0,510,270,390,400,460,23
Kyowa Kirin Stock
Kyowa Kirin
SupplierCustomer0,220,350,740,860,73-
Nomura Holdings Stock
Nomura Holdings
SupplierCustomer0,18-0,09-0,24-0,500,720,52
Ohki Health Care Holdings Stock
Ohki Health Care Holdings
SupplierCustomer0,15-0,510,060,590,900,81
Mitsubishi UFJ Financial Group Stock
Mitsubishi UFJ Financial Group
SupplierCustomer-0,06-0,68-0,75-0,66-0,58
Sanofi Stock
Sanofi
SupplierCustomer-0,38-0,56-0,58-0,68-0,54-0,62
1

Most common questions regarding Hisamitsu Pharmaceutical Co

What values and corporate philosophy does Hisamitsu Pharmaceutical Co represent?

Hisamitsu Pharmaceutical Co Inc represents values of innovation, quality, and commitment to improving healthcare. With a strong corporate philosophy, the company aims to provide effective and safe pharmaceutical products to enhance people's well-being. Its focus on research and development has led to breakthroughs in drug delivery systems, including its flagship product, the PAIN PATCH. By continuously investing in technological advancements and maintaining high standards, Hisamitsu Pharmaceutical Co Inc sets itself apart as a trusted and reputable company in the pharmaceutical industry.

In which countries and regions is Hisamitsu Pharmaceutical Co primarily present?

Hisamitsu Pharmaceutical Co Inc is primarily present in Japan, where it is headquartered and has a strong market presence. As a leading pharmaceutical company, Hisamitsu has expanded its operations internationally and is also present in various countries and regions worldwide. Some of the key markets where Hisamitsu Pharmaceutical Co Inc operates include the United States, Europe, China, Asia-Pacific, and other regions. With its diverse range of healthcare products and global reach, Hisamitsu Pharmaceutical Co Inc continues to contribute to the well-being of people across different countries and regions.

What significant milestones has the company Hisamitsu Pharmaceutical Co achieved?

Some significant milestones achieved by Hisamitsu Pharmaceutical Co Inc include the development of the world's first topical patch for pain relief, the launch of their flagship product Salonpas, which has become a globally recognized brand, and their continuous research and development efforts in pharmaceutical technology. Additionally, Hisamitsu Pharmaceutical Co Inc has expanded its global presence through strategic partnerships and acquisitions, strengthening its position in the international market. Their commitment to innovation and high-quality healthcare products has garnered them numerous accolades and recognition within the industry.

What is the history and background of the company Hisamitsu Pharmaceutical Co?

Hisamitsu Pharmaceutical Co Inc is a renowned Japanese company with a rich history and background in the pharmaceutical industry. Founded in 1847, Hisamitsu has been dedicated to providing innovative healthcare solutions to improve people's lives. With a focus on the development and manufacturing of pharmaceutical products, the company has established itself as a leader in transdermal drug delivery systems. Hisamitsu Pharmaceutical Co Inc has grown into a global entity, operating in various countries and expanding its product portfolio to include a wide range of over-the-counter medicines, medical devices, and prescription drugs. With a commitment to research, quality, and customer satisfaction, Hisamitsu continues to contribute to the advancement of healthcare worldwide.

Who are the main competitors of Hisamitsu Pharmaceutical Co in the market?

The main competitors of Hisamitsu Pharmaceutical Co Inc in the market include large pharmaceutical companies such as Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company Limited, and Astellas Pharma Inc. Additionally, other competitors may include global pharmaceutical companies like Pfizer Inc. and Novartis AG. These companies compete with Hisamitsu Pharmaceutical Co Inc in various therapeutic areas, including pain management and patches.

In which industries is Hisamitsu Pharmaceutical Co primarily active?

Hisamitsu Pharmaceutical Co Inc is primarily active in the pharmaceutical industry.

What is the business model of Hisamitsu Pharmaceutical Co?

The business model of Hisamitsu Pharmaceutical Co Inc focuses on the development, manufacturing, and sales of pharmaceutical products. As a leading Japanese pharmaceutical company, Hisamitsu Pharmaceutical specializes in producing transdermal therapeutic patches, such as the popular brand Salonpas. By utilizing innovative drug delivery systems and advanced research, the company aims to provide effective and convenient solutions for pain relief and healthcare. With a strong emphasis on quality and customer satisfaction, Hisamitsu Pharmaceutical continues to expand its product portfolio and global presence, addressing the diverse healthcare needs of individuals worldwide.

What is the P/E ratio of Hisamitsu Pharmaceutical Co 2024?

The Hisamitsu Pharmaceutical Co P/E ratio is 22.58.

What is the P/S ratio of Hisamitsu Pharmaceutical Co 2024?

The Hisamitsu Pharmaceutical Co P/S ratio is 2.23.

What is the AlleAktien quality score of Hisamitsu Pharmaceutical Co?

The AlleAktien quality score for Hisamitsu Pharmaceutical Co is 5/10.

What is the revenue of Hisamitsu Pharmaceutical Co 2024?

The Hisamitsu Pharmaceutical Co revenue is 141.71 B JPY.

How high is the profit of Hisamitsu Pharmaceutical Co 2024?

The Hisamitsu Pharmaceutical Co profit is 13.97 B JPY.

What is the business model of Hisamitsu Pharmaceutical Co

Hisamitsu Pharmaceutical Co Inc is a Japanese company specializing in the manufacture and sale of pharmaceutical products. It has a wide range of medicines for the treatment of musculoskeletal, respiratory, cardiovascular, and skin disorders. The business model of Hisamitsu is based on researching and developing new drugs, as well as marketing and distributing these products globally. The company conducts research and development worldwide to continuously expand its product range and meet the needs of consumers. Hisamitsu's medicines are divided into different categories, including pain relief, dermatology, gastroenterology, and respiratory diseases. In the pain relief category, the company offers various products such as pain patches, ointments, and creams used to relieve joint pain, muscle soreness, and other pain symptoms. In the dermatology category, Hisamitsu produces innovative medications for the treatment of skin diseases such as acne, eczema, and dermatitis. In the gastroenterology category, Hisamitsu offers medications for the treatment of gastrointestinal disorders such as heartburn, acid reflux, and digestive disorders. In the respiratory diseases category, the company provides products for the treatment of conditions like asthma, chronic obstructive pulmonary disease (COPD), and seasonal allergic rhinitis. Hisamitsu has a wide distribution network and sells its products in over 60 countries worldwide. It collaborates with various partners, retailers, and health organizations to ensure that its products are available in every region globally. The company also operates an extensive research and development department to further develop its innovative medications. It invests significant resources in the search for new active ingredients that can be used to treat conditions that have not been addressed previously. Hisamitsu's business model also includes collaboration with other companies to develop and jointly market innovative products. Collaborating with other manufacturers allows Hisamitsu to diversify its product range and reach a broader customer base. Overall, Hisamitsu's business model is based on a combination of research and development, distribution partnerships, and a strong presence in the global market. With a wide range of innovative pharmaceutical products and a strong commitment to research and development of new medications, Hisamitsu Pharmaceutical Co Inc has established a leading position in the pharmaceutical industry and will play an important role in improving the health and well-being of people worldwide in the future.

What is the Hisamitsu Pharmaceutical Co dividend?

Hisamitsu Pharmaceutical Co pays a dividend of 42.25 JPY distributed over payouts per year.

How often does Hisamitsu Pharmaceutical Co pay dividends?

The dividend cannot currently be calculated for Hisamitsu Pharmaceutical Co or the company does not pay out a dividend.

What is the Hisamitsu Pharmaceutical Co ISIN?

The ISIN of Hisamitsu Pharmaceutical Co is JP3784600003.

What is the Hisamitsu Pharmaceutical Co WKN?

The WKN of Hisamitsu Pharmaceutical Co is 864341.

What is the Hisamitsu Pharmaceutical Co ticker?

The ticker of Hisamitsu Pharmaceutical Co is 4530.T.

How much dividend does Hisamitsu Pharmaceutical Co pay?

Over the past 12 months, Hisamitsu Pharmaceutical Co paid a dividend of 44.5 JPY . This corresponds to a dividend yield of about 1.09 %. For the coming 12 months, Hisamitsu Pharmaceutical Co is expected to pay a dividend of 45.42 JPY.

What is the dividend yield of Hisamitsu Pharmaceutical Co?

The current dividend yield of Hisamitsu Pharmaceutical Co is 1.09 %.

When does Hisamitsu Pharmaceutical Co pay dividends?

Hisamitsu Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of September, March, September, March.

How secure is the dividend of Hisamitsu Pharmaceutical Co?

Hisamitsu Pharmaceutical Co paid dividends every year for the past 23 years.

What is the dividend of Hisamitsu Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 45.42 JPY are expected. This corresponds to a dividend yield of 1.11 %.

In which sector is Hisamitsu Pharmaceutical Co located?

Hisamitsu Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Hisamitsu Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Hisamitsu Pharmaceutical Co from 11/1/2024 amounting to 2 JPY, you needed to have the stock in your portfolio before the ex-date on 8/29/2024.

When did Hisamitsu Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 11/1/2024.

What was the dividend of Hisamitsu Pharmaceutical Co in the year 2023?

In the year 2023, Hisamitsu Pharmaceutical Co distributed 42.75 JPY as dividends.

In which currency does Hisamitsu Pharmaceutical Co pay out the dividend?

The dividends of Hisamitsu Pharmaceutical Co are distributed in JPY.

All fundamentals about Hisamitsu Pharmaceutical Co

Our stock analysis for Hisamitsu Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Hisamitsu Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.